Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: wherein: G is &mdash；N&boxH； or &mdash；CH&boxH；； D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members； R6 is hydrogen or optionally substituted C1-C3 alkyl； P represents hydrogen and U represents a radical of formula (IA)； or U represents hydrogen and P represents a radical of formula -A-(CH2)z&mdash；X1-L1-Y&mdash；NH&mdash；CHR1R2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members； z, Y, L1, and X1 are as defined in the specification； R1 is a carboxylic acid group (&mdash；COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group； and R2 is the side chain of a natural or non-natural alpha amino acid.
